MDGL

Madrigal Pharmaceuticals Inc

Aug 13 • 04:00PM ET

373.46

Dollar change +14.46
Percentage change 4.03	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD AKRO VKTX NBIX ENTA SLDB LXRX TSHA IMAB RDHL

| Held by: VTI IWM VB XBI VBR VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-12.85	Insider Own	9.57%	Shs Outstand	22.22M	Perf Week	10.46%
Market Cap	8.32B	Forward P/E	84.05	EPS next Y	4.44	Insider Trans	-14.22%	Shs Float	20.16M	Perf Month	20.03%
Enterprise Value	7.65B	PEG	-	EPS next Q	-2.08	Inst Own	107.92%	Short Float	19.74%	Perf Quarter	26.44%
Income	-281.90M	P/S	16.15	EPS this Y	56.79%	Inst Trans	5.75%	Short Ratio	11.16	Perf Half Y	12.56%
Sales	515.55M	P/B	11.92	EPS next Y	146.95%	ROA	-26.65%	Short Interest	3.98M	Perf YTD	21.03%
Book/sh	31.32	P/C	10.38	EPS next 5Y	-	ROE	-36.30%	52W High	377.46 -1.06%	Perf Year	57.58%
Cash/sh	35.98	P/FCF	-	EPS past 3/5Y	-14.40% -32.06%	ROIC	-34.43%	52W Low	200.63 86.14%	Perf 3Y	387.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.01%	Volatility	3.50% 4.83%	Perf 5Y	262.23%
Dividend TTM	-	EV/Sales	14.83	EPS Y/Y TTM	49.62%	Oper. Margin	-60.09%	ATR (14)	14.70	Perf 10Y	417.98%
Dividend Ex-Date	-	Quick Ratio	4.78	Sales Y/Y TTM	3421.98%	Profit Margin	-54.68%	RSI (14)	74.98	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	5.11	EPS Q/Q	73.19%	SMA20	15.38%	Beta	-1.04	Target Price	448.33
Payout	-	Debt/Eq	0.18	Sales Q/Q	1353.76%	SMA50	21.95%	Rel Volume	2.09	Prev Close	359.00
Employees	528	LT Debt/Eq	0.18	Earnings	Aug 05 BMO	SMA200	19.57%	Avg Volume	356.67K	Price	373.46
IPO	Feb 06, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	46.54% 31.33%	Trades		Volume	730,938	Change	4.03%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy	$236 → $422
Feb-27-25	Reiterated	H.C. Wainwright	Buy	$400 → $405
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform	$382
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy	$195
Nov-24-20	Resumed	Evercore ISI	Outperform	$180
Nov-06-20	Reiterated	H.C. Wainwright	Buy	$165 → $184
Jul-31-20	Initiated	Piper Sandler	Overweight	$208
Jun-05-20	Initiated	BMO Capital Markets	Market Perform	$135

Show Previous Ratings

Aug-12-25 09:00AM	Credo AI Launches Advisory Services to Make Trusted AI Governance Real, Auditable, and Measurable (Business Wire)
Aug-11-25 08:00AM	Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-08-25 06:35PM	Madrigal Pharmaceuticals CEO: We're positioned for decades of growth (CNBC TV)
Aug-07-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
08:15AM	Loading…
Aug-05-25 08:15AM	Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.59%
07:11AM	Madrigal: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Jul-30-25 08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
05:00AM	Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited (GlobeNewswire)
Jul-25-25 10:42PM	Madrigal Pharmaceuticals, Inc. (MDGL)'s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 (Insider Monkey)
08:00AM	Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion (Insider Monkey)
Jul-22-25 08:00AM	Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH (GlobeNewswire) -5.30%
Jul-17-25 11:34AM	MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights (Zacks)
07:10AM	Loading…
07:10AM	Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Jul-16-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.87%
08:00AM	Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra (Resmetirom) (GlobeNewswire)
Jul-02-25 02:46AM	JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential (Insider Monkey)
Jun-24-25 12:45PM	Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra (Insider Monkey)
Jun-20-25 12:04PM	Madrigal poised to enter European MASH market after CHMP endorsement (Pharmaceutical Technology)
06:30AM	Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
Jun-17-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 08:00AM	Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference (GlobeNewswire)
May-26-25 11:15AM	Short Report: Bears bite into Krispy Kreme after another weak earnings report (TipRanks)
May-15-25 07:21PM	John Paulson's Strategic Move: Honeywell International Inc. Takes Center Stage (GuruFocus.com)
May-13-25 09:45AM	2 Monster Stocks in the Making to Buy Now and Hold for 10 Years (Motley Fool)
May-10-25 07:15AM	Madrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
May-08-25 11:41PM	Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker's Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 08:47AM	Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson's Stocks with Huge Upside Potential (Insider Monkey)
03:02AM	Loading…
May-02-25 03:02AM	Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
May-01-25 10:57PM	Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:01PM	Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:40AM	Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
08:20AM	Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:17AM	Madrigal: Q1 Earnings Snapshot (Associated Press Finance)
07:17AM	Madrigals MASH drug sales again top Wall Street projections (BioPharma Dive)
07:00AM	Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-29-25 08:00AM	Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress (GlobeNewswire)
Apr-18-25 08:00AM	Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 (GlobeNewswire)
04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 10:28AM	89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development (Seeking Alpha)
Apr-16-25 07:00AM	Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer (GlobeNewswire)
Apr-15-25 02:37PM	Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (Seeking Alpha)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha)
Mar-28-25 06:54PM	Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March? (Insider Monkey)
11:30AM	Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-21-25 08:30AM	Artisan International Small-Mid Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 10:34PM	Tracking John Paulson's Paulson & Co. Portfolio - Q4 2024 Update (SeekingAlpha)
Mar-18-25 05:28AM	Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-11-25 08:00AM	Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors (GlobeNewswire)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Feb-28-25 10:20AM	Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA (TipRanks)
Feb-27-25 02:05AM	Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -5.66%
Feb-26-25 11:43PM	Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +14.99%
12:28PM	Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis (Benzinga)
11:27AM	Why Madrigal Pharmaceuticals Stock Is Soaring Today (Motley Fool)
07:21AM	Madrigal: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
06:30AM	Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
Feb-21-25 08:00AM	Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-12-25 08:00AM	Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 (GlobeNewswire)
Jan-17-25 08:28AM	Why Madrigal Pharmaceuticals Stock Was Plummeting This Week (Motley Fool) +7.64%
Jan-13-25 11:20AM	Why Madrigal Pharmaceuticals Stock Is Sinking Today (Motley Fool) -10.39%
06:45AM	Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra (GlobeNewswire)
Jan-03-25 08:00AM	Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-06-24 06:46AM	Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities (TipRanks)
Nov-23-24 07:46AM	3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move (Motley Fool)
Nov-22-24 09:55AM	Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +5.53%
Nov-21-24 05:12PM	Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-18-24 02:53AM	The first MASH drug could open the door for others including GLP-1s (Pharma Voice) +5.17%
Nov-14-24 09:12PM	John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC (GuruFocus.com)
Nov-10-24 09:30AM	1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More (Motley Fool)
Nov-06-24 08:00AM	Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 09:55AM	Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations (GuruFocus.com)
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:17PM	Madrigal Pharmaceuticals stock jumps on MASH drug hopes (Yahoo Finance Video) +23.23%
04:08PM	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH (Investor's Business Daily)
03:03AM	Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ... (GuruFocus.com)
Oct-31-24 07:28AM	Madrigal: Q3 Earnings Snapshot (Associated Press Finance) +20.10%
07:00AM	Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Oct-30-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting (GlobeNewswire)
Oct-22-24 06:53AM	Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug (Clinical Trials Arena)
Oct-21-24 08:00AM	Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis (GlobeNewswire)
Oct-18-24 08:00AM	Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 (GlobeNewswire)
Oct-16-24 08:44AM	Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra (Insider Monkey)
Oct-02-24 08:00AM	Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference (GlobeNewswire)
Oct-01-24 08:00AM	Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development (GlobeNewswire)
Sep-30-24 08:00AM	Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra (resmetirom) (GlobeNewswire)
Sep-25-24 12:03AM	Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now? (Insider Monkey)
Aug-26-24 08:00AM	Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-17-24 10:15AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
Aug-14-24 11:55PM	John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc (GuruFocus.com)
06:00AM	This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock (Motley Fool)
Aug-13-24 11:33AM	Madrigal plans to solidify Rezdiffras position in MASH despite start being slower than expected (Pharmaceutical Technology)
Aug-08-24 03:47AM	Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily) -12.18%
11:12AM	Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line (Zacks)
07:20AM	Madrigal: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRIEDMAN PAUL A	Director	Aug 13 '25	Option Exercise	9.45	129,172	1,220,675	316,336	Aug 13 06:18 PM
FRIEDMAN PAUL A	Director	Aug 13 '25	Sale	370.24	129,172	47,825,149	187,164	Aug 13 06:18 PM
FRIEDMAN PAUL A	Director	Aug 12 '25	Option Exercise	9.45	43,605	412,067	230,769	Aug 13 05:45 PM
FRIEDMAN PAUL A	Director	Aug 11 '25	Option Exercise	9.45	3,203	30,268	190,367	Aug 13 05:45 PM
FRIEDMAN PAUL A	Director	Aug 12 '25	Sale	355.68	43,605	15,509,469	187,164	Aug 13 05:45 PM
FRIEDMAN PAUL A	Director	Aug 11 '25	Sale	350.27	3,203	1,121,917	187,164	Aug 13 05:45 PM
Taub Rebecca	Director	Aug 12 '25	Option Exercise	9.45	43,263	408,835	504,307	Aug 13 05:33 PM
Taub Rebecca	Director	Aug 11 '25	Option Exercise	9.45	3,200	30,240	464,244	Aug 13 05:33 PM
Taub Rebecca	Director	Aug 12 '25	Sale	355.69	43,263	15,388,279	461,044	Aug 13 05:33 PM
Taub Rebecca	Director	Aug 11 '25	Sale	350.24	3,200	1,120,753	461,044	Aug 13 05:33 PM
PAUL FRIEDMAN	Director	Aug 13 '25	Proposed Sale	359.00	129,172	46,372,748		Aug 13 04:22 PM
REBECCA TAUB	Director	Aug 12 '25	Proposed Sale	349.50	43,263	15,120,418		Aug 12 04:27 PM
PAUL FRIEDMAN	Director	Aug 12 '25	Proposed Sale	349.50	43,605	15,239,948		Aug 12 04:26 PM
PAUL FRIEDMAN	Director	Aug 11 '25	Proposed Sale	345.73	3,203	1,107,373		Aug 11 04:26 PM
REBECCA TAUB	Director	Aug 11 '25	Proposed Sale	345.73	3,200	1,106,336		Aug 11 04:26 PM
Taub Rebecca	Director	Jul 18 '25	Option Exercise	9.45	1,000	9,450	462,044	Jul 22 05:08 PM
Taub Rebecca	Director	Jul 18 '25	Sale	350.00	1,000	350,005	461,044	Jul 22 05:08 PM
FRIEDMAN PAUL A	Director	Jul 18 '25	Option Exercise	9.45	1,400	13,230	188,564	Jul 22 05:06 PM
FRIEDMAN PAUL A	Director	Jul 18 '25	Sale	350.03	1,400	490,044	187,164	Jul 22 05:06 PM
PAUL FRIEDMAN	Director	Jul 18 '25	Proposed Sale	348.73	1,400	488,222		Jul 18 05:25 PM
REBECCA TAUB	Director	Jul 18 '25	Proposed Sale	348.73	1,000	348,730		Jul 18 05:03 PM
FRIEDMAN PAUL A	Director	Jul 16 '25	Option Exercise	9.45	26,176	247,363	213,340	Jul 18 04:13 PM
FRIEDMAN PAUL A	Director	Jul 17 '25	Option Exercise	9.45	2,700	25,515	189,864	Jul 18 04:13 PM
FRIEDMAN PAUL A	Director	Jul 16 '25	Sale	353.47	26,176	9,252,543	187,164	Jul 18 04:13 PM
FRIEDMAN PAUL A	Director	Jul 17 '25	Sale	350.48	2,700	946,301	187,164	Jul 18 04:13 PM
Taub Rebecca	Director	Jul 16 '25	Option Exercise	9.45	26,444	249,896	487,488	Jul 18 04:11 PM
Taub Rebecca	Director	Jul 17 '25	Option Exercise	9.45	2,657	25,109	463,701	Jul 18 04:11 PM
Taub Rebecca	Director	Jul 16 '25	Sale	353.47	26,444	9,347,063	461,044	Jul 18 04:11 PM
Taub Rebecca	Director	Jul 17 '25	Sale	350.41	2,657	931,035	461,044	Jul 18 04:11 PM
REBECCA TAUB	Director	Jul 17 '25	Proposed Sale	344.97	2,657	916,585		Jul 17 04:21 PM
PAUL FRIEDMAN	Director	Jul 17 '25	Proposed Sale	344.97	2,700	931,419		Jul 17 04:20 PM
PAUL FRIEDMAN	Director	Jul 16 '25	Proposed Sale	311.14	26,176	8,144,401		Jul 16 04:20 PM
REBECCA TAUB	Director	Jul 16 '25	Proposed Sale	311.14	26,444	8,227,786		Jul 16 04:19 PM
CRAVES FRED B	Director	Mar 12 '25	Option Exercise	100.77	7,728	778,784	357,804	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 13 '25	Option Exercise	65.06	7,742	503,695	357,818	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 12 '25	Sale	331.84	7,728	2,564,426	350,076	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 13 '25	Sale	325.25	7,742	2,518,053	350,076	Mar 14 04:25 PM
FRED CRAVES	Director	Mar 13 '25	Proposed Sale	325.25	7,742	2,518,054		Mar 13 05:03 PM
Dier Mardi	SVP and CFO	Mar 10 '25	Sale	323.04	258	83,344	10,440	Mar 12 04:32 PM
FRED CRAVES	Director	Mar 12 '25	Proposed Sale	331.92	7,428	2,465,514		Mar 12 04:11 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 05 '25	Option Exercise	87.49	14,113	1,234,766	17,841	Mar 07 05:40 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 05 '25	Sale	341.32	14,113	4,817,104	3,728	Mar 07 05:40 PM
Kelley Shannon T	General Counsel	Mar 03 '25	Sale	335.00	415	139,025	7,290	Mar 05 04:36 PM
Dier Mardi	SVP and CFO	Mar 03 '25	Sale	324.96	1,961	637,248	6,914	Mar 05 04:31 PM
Huntsman Carole	Chief Commercial Officer	Mar 03 '25	Sale	325.98	1,834	597,840	8,604	Mar 05 04:24 PM
ROBERT WALTERMIRE	Officer	Mar 05 '25	Proposed Sale	341.32	14,113	4,817,104		Mar 05 04:07 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Feb 28 '25	Sale	341.07	1,227	418,488	3,728	Mar 04 09:24 PM
Mardi Dier	Officer	Mar 03 '25	Proposed Sale	325.89	1,187	386,834		Mar 03 08:27 PM
SHANNON KELLEY	Officer	Mar 03 '25	Proposed Sale	341.27	415	141,627		Mar 03 04:51 PM
CAROLE A HUNTSMAN	Officer	Mar 03 '25	Proposed Sale	341.27	1,834	625,889		Mar 03 04:12 PM
ROBERT WALTERMIRE	Officer	Feb 28 '25	Proposed Sale	341.07	1,227	418,488		Feb 28 04:59 PM
Daly James M	Director	Feb 27 '25	Option Exercise	82.90	15,470	1,282,478	17,382	Feb 28 04:31 PM
Daly James M	Director	Feb 27 '25	Sale	347.45	15,470	5,375,126	1,912	Feb 28 04:31 PM
BATE KENNETH	Director	Feb 27 '25	Option Exercise	66.26	20,000	1,325,287	21,912	Feb 28 04:30 PM
BATE KENNETH	Director	Feb 27 '25	Sale	356.44	20,000	7,128,759	1,912	Feb 28 04:30 PM
JAMES M DALY	Director	Feb 27 '25	Proposed Sale	347.45	15,470	5,375,126		Feb 27 04:54 PM
KENNETH M BATE	Director	Feb 27 '25	Proposed Sale	356.44	20,000	7,128,758		Feb 27 04:51 PM
Huntsman Carole	Chief Commercial Officer	Jan 24 '25	Sale	335.24	347	116,328	10,438	Jan 27 05:18 PM
Sibold William John	President and CEO	Jan 24 '25	Sale	335.24	1,584	531,020	54,303	Jan 27 05:12 PM
Taub Rebecca	Pres., R&D, and CMO	Jan 24 '25	Sale	335.24	648	217,236	456,662	Jan 27 05:07 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jan 24 '25	Sale	335.24	103	34,530	4,955	Jan 27 05:03 PM
Rebecca Taub	Officer	Jan 24 '25	Proposed Sale	340.14	648	220,411		Jan 24 06:00 PM
William John Sibold	Officer	Jan 24 '25	Proposed Sale	340.14	1,584	538,782		Jan 24 06:00 PM
Carole Huntsman	Officer	Jan 24 '25	Proposed Sale	340.14	347	118,029		Jan 24 06:00 PM
Robert E Waltermire	Officer	Jan 24 '25	Proposed Sale	340.14	103	35,034		Jan 24 06:00 PM
Kelley Shannon T	General Counsel	Jan 17 '25	Sale	273.41	277	75,735	7,705	Jan 17 07:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jan 17 '25	Sale	273.41	442	120,847	5,058	Jan 17 07:08 PM
Taub Rebecca	Pres., R&D, and CMO	Jan 17 '25	Sale	273.41	1,689	461,789	457,310	Jan 17 07:05 PM
Rebecca Taub	Officer	Jan 17 '25	Proposed Sale	272.79	1,689	460,742		Jan 17 05:30 PM
Shannon Kelley	Officer	Jan 17 '25	Proposed Sale	272.79	277	75,563		Jan 17 05:30 PM
Robert E Waltermire	Officer	Jan 17 '25	Proposed Sale	272.79	442	120,573		Jan 17 05:30 PM
CRAVES FRED B	Director	Dec 03 '24	Sale	315.31	3,600	1,135,122	11,000	Dec 05 04:46 PM
CRAVES FRED B	Director	Nov 25 '24	Sale	350.30	3,400	1,191,028	14,600	Nov 27 04:16 PM
CRAVES FRED B	Director	Nov 25 '24	Proposed Sale	322.73	10,000	3,227,300		Nov 25 04:10 PM
Huntsman Carole	Chief Commercial Officer	Nov 21 '24	Sale	316.92	688	218,041	10,785	Nov 22 04:30 PM
Carole Huntsman	Officer	Nov 21 '24	Proposed Sale	316.92	688	218,040		Nov 21 04:30 PM
Levy Richard S	Director	Nov 07 '24	Option Exercise	7.36	5,000	36,800	16,012	Nov 08 05:07 PM
Levy Richard S	Director	Nov 07 '24	Sale	350.00	5,000	1,750,000	11,012	Nov 08 05:07 PM
RICHARD S LEVY	Director	Nov 07 '24	Proposed Sale	338.22	5,000	1,691,100		Nov 07 04:36 PM
Levy Richard S	Director	Nov 01 '24	Option Exercise	7.36	5,000	36,800	16,012	Nov 05 07:01 PM
Levy Richard S	Director	Nov 01 '24	Sale	300.94	5,000	1,504,703	11,012	Nov 05 07:01 PM
RICHARD S LEVY	Director	Nov 01 '24	Proposed Sale	259.34	5,000	1,296,700		Nov 01 04:47 PM
Sibold William John	President and CEO	Sep 09 '24	Sale	243.83	6,363	1,551,490	55,887	Sep 11 09:51 PM
William John Sibold	Officer	Sep 09 '24	Proposed Sale	243.83	6,363	1,551,514		Sep 10 09:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDGL

Madrigal Pharmaceuticals Inc

Upgrade your FINVIZ experience